Although the SLC22A16-OCI-Ly7 cells did not have a statistically significant increase in 14C-doxorubicin uptake or inhibition of proliferation, the results were consistent over three experiments, and were similar to SLC22A16 in overexpression models.33, 34 Furthermore, OCI-Ly3 and SUDHL4 DLBCL cell lines showed a similar proliferation response upon SLC22A16 overexpresssion (Supplementary Figure 6). The gene discussed is SLC22A16; the disease is diffuse large B-cell lymphoma.